Researchers from the National Institutes of Health tested the drug in an experiment of cell cultures with live viruses, finding it can reduce COVID-19 infections by targeting an enzyme the virus needs to make copies of itself inside the body.
“We urgently need additional effective, accessible treatments for COVID-19,” Diana Bianchi, MD, director of the NIH’s National Institute of Child Health and Human Development, said in a news release. “An oral drug that prevents SARS-CoV-2 from replicating would be an important tool for reducing the severity of the disease.”
The NIH said it will conduct more preliminary studies on Tempo l and plans to study the drug in a clinical study of COVID-19.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
